Last reviewed · How we verify
NCT07051213: BeSolveRD
The Belgian Genome Resource to Resolve Rare Diseases
NA trial testing Whole exome sequencing in Intellectual Developmental Disorder in 567 participants. Completed in 31 January 2025.
5 July 2024
Quick facts
| Lead sponsor | Universitaire Ziekenhuizen KU Leuven |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 567 |
| Start date | 2 June 2021 |
| Primary completion | 5 July 2024 |
| Estimated completion | 31 January 2025 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- Whole exome sequencing
- Whole genome Sequencing
Conditions studied
- Intellectual Developmental Disorder — all drugs for Intellectual Developmental Disorder →
- Malformations — all drugs for Malformations →
- Dysmorphia — all drugs for Dysmorphia →
- Developmental Delay (Disorder) — all drugs for Developmental Delay (Disorder) →
Sponsor
Universitaire Ziekenhuizen KU Leuven — full company profile →
Who can join
Eligibility, any sex, with Intellectual Developmental Disorder or Malformations. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Whole-exome (WES) or whole-genome sequencing (WGS) are recommended as first- or second-tier molecular tests for patients with developmental disorders (DD), but the clinical utility of WGS continues to be debated. This prospective randomized trial involving all Belgian Human Genetics centers compares the standard of care (SoC) - combining WES and microarray or shallow WGS - with WGS for 567 individuals with unexplained DD. The aim of the project is to pave the way towards diagnostic implementation of WGS for rare DD in Belgium. To reach this aim, (1) technical validation is performed at different genetic centres in Belgium, (2) clinical utility of WGS is explored and (3) the health economic impact is mapped.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07051213
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Whole exome sequencing
Trials testing the same drug.
- NCT04528303 — Whole Genome Sequencing Versus Whole Exome Sequencing for Congenital Diarrhea and Enteropahty · NA · recruiting
- NCT05736237 — Identification and Verification of Candidate Genes Responsible for Optic Disc Drusen Development · completed
- NCT06001957 — Whole Exome Sequencing in Coronary Artery Ectasia · completed
- NCT03979833 — Drivers of Hypoxia-induced Angiogenesis in Tumor Development · unknown
- NCT03857607 — Natural History Study of ATP1A3-related Disease · unknown
Other recruiting trials for Intellectual Developmental Disorder
Currently open trials in the same condition.
- NCT07302048 — Impact and Determinants of Success of a Mobile Multidisciplinary Intervention System Specialized in Pain Management for · NA · recruiting
Other Universitaire Ziekenhuizen KU Leuven trials
Trials by the same sponsor.
- NCT06831955 — LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer · Phase 2 · recruiting
- NCT07356505 — Efficacy and Safety of Micra AV2 Transcatheter Pacing System · NA · recruiting
- NCT07286968 — Gastro-Intestinal Digestion and Physiology After Bariatric Surgery · recruiting
- NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
- NCT07270536 — Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07051213 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitaire Ziekenhuizen KU Leuven
- Last refreshed: 4 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07051213.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing